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ABSTRACT
Introduction Hepatitis C Virus (HCV) recently was identified as a major cause of post 
transfusion hepatitis world wide. To evaluate the role of blood transfusion on 
the prevalence of  HCV infection, by testing antibody and RNA  as well as 
the genotypes of HCV .Also to detect if Blood transfusion acts as 
unconfounding risk factor for HCV infection.
Methods Sera from 3491 pregnant women were investigated for the presence of HCV 
antibodies (anti-HCV) by using third generation enzyme immunoassay (EIA-
3) as screening test, followed by immunoblot assay (Lia Tek-III). In addition 
94 sera of studied women were subjected to molecular analysis (at 
laboratories of Sorin BioMedica – Italy) for the detection of viral RNA and 
genotypes of HCV. Using RT-PCR & DNA Enzyme immunoassay (DEIA) 
method.
Results Our study revealed, that seroprevalence rate of HCV specific Ab & RNA 
were significantly higher (16.32 %, 80% respectively) among women with a 
history of blood transfusion, compared to those (2.53%, 56.5%) with no such 
history P=0.0001, P=0.01. And there is a significant direct linear correlation 
between number of blood transfused and the seropositive rate of anti-HCV 
(r=0.7, p=0.046). Based on multivariate analysis, interestingly, this study 
confirmed that, blood transfusion significantly acting as unconfounding risk 
factor for acquiring HCV infection (Adjusted OR=1.938,95% C.I=1.646-
2.28). And the risk of exposure is increases with increased number of blood 
transfused. Although, we found no significant association between, HCV 
genotypic distribution and history of blood transfusion. However, high 
proportion of women with a history of blood transfusion were  harboring  
HCV genotype –4 or 1b, 50%,40%, resepctively.
Conclusions Our study shows, evidence that, blood transfusion acts as unconfounding risk 
factor for acquiring and in a mode of transmission of HCV infection. 
Therefore strict screening of blood donor for HCV-Abs and / or RNA is 
highly recommended.
Keywords HCV - mod of transmission - blood transfusion
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INTRODUCTION
Hepatitis C (HCV) is an infectious disease 
affecting the liver caused by the hepatitis C virus 
(HCV) 1. It is a systemic disease and patients may 
experience a wide spectrum of clinical 
manifestations ranging from an absence of 
symptoms to a more symptomatic illness prior to 
the development of advanced liver disease2. (HCV) 
is recognized as an important cause of chronic 
hepatitis, cirrhosis, and hepatocellular carcinoma3, 4, 
5, 6. Interestingly, an estimated 270-300 million 
people worldwide are infected with hepatitis7.
The hepatitis C virus is transmitted by 
blood-to-blood contact 8 according to Centers for 
Disease Control; hepatitis C virus is spread by 
exposure to large quantities of blood, either 
through the skin or by injection 9. Therefore, blood 
transfusion, blood products, or organ 
transplantation prior to implementation of HCV 
screening is all risk factors for hepatitis C10. A 
cDNA clone from the hepatitis C virus genome was 
first isolated in 198910 and reliable tests to screen 
for the virus were not available until 1992. 
Therefore, those who received blood or blood 
products prior to the implementation of screening 
the blood supply for HCV may have been exposed 
to the virus11. Therefore, in the 1970s and 1980s, 
posttransfusional non-A, non-B hepatitis was the 
most frequent infection transmitted by blood and 
blood products, representing 80 to 90% of all cases 
of posttransfusional hepatitis)12 and with the 
introduction of tests to detect these antibodies in 
the screening of blood units, there was a sharp drop 
in posttransfusional hepatitis13, 14, 15, 16 . So there has 
not been a documented transfusion-related case of 
hepatitis C in the United States for over a decade, 
as the blood supply is vigorously screened with 
both EIA and PCR technologies11, 17.
Anti-HCV antibodies indicate exposure to 
the virus, but cannot determine if ongoing infection 
is present. All persons with positive anti-HCV 
antibody tests must undergo additional testing for 
the presence of the hepatitis C virus itself to 
determine whether current infection is present. The 
presence of the virus is tested for using molecular 
nucleic acid testing methods, such as polymerase 
chain reaction (PCR) 18.
In Iraq, the prevalence of post transfusion 
hepatitis C is not known. Therefore we conducted 
our study among pregnant women to determine the 
prevalence of PTHCV using HCV anti bodies and 
HCV-RNA. 
OBJECTIVES
The aims of this study are to assess the prevalence 
of post transfusion hepatitis C virus, to detect if 
blood transfusion acts as unconfounding risk factor 
for HCV infection, to identify the predominant 
HCV genotype(s) in post-transfusional hepatitis C 
virus.
METHODS
A sample of 3491 apparently healthy pregnant 
women, during third trimester was chosen 
randomly from 19 health care units located all over 
Baghdad. All pregnant women were interviewed by 
the same researcher, in order to avoid 
misclassification bias, using a brief specific 
questionnaire that focused on history of blood 
transfusion, date and number of blood unit 
transfused.
From each participant serum sample was 
obtained, and dispensed into two screw capped 
frozen tubes, stored at –20oC and -70oC for the 
antibody testing and molecular analysis 
respectively. Initial screening of HCV antibody 
was carried out, using third generation enzyme 
immunoassay (EIA-3). Then after, the positive 
results were confirmed further by the third
generation immunoblot assay Lia-Tek III. Only 
reactive Lia-Tek III were considerable as positive 
serum samples. Furthermore, 94 serum samples 
(stored at –70oC) were transferred by researcher to 
laboratories of Sorin Diagnostica (Sallugia, Italy) 
to be subjected to molecular analysis using the 
most recently advanced method RT-PCR and DNA 
enzyme immunoassay (DEIA) method .In which 
each sample was subjected to extraction of RNA 
followed by synthesis of complementary DNA 
(cDNA). After amplification of newly synthesized 
cDNA was carried out, finally detection of RNA 
and genotypes of HCV using DEIA method. This 
method is based on hybridization of the 
complementary (cDNA) with a single standard 
DNA probe coated on the wall of the micro titer 
plate wells with streptavidin-biotin band. Detection 
of hybridization is achieved by the use of anti-
double stranded DNA monoclonal antibody. 
Finally, the result was detected by 
spectrophotometer. Depending on Simmond’s 
Nomenclature for HCV genotypic classification 
that was proposed by international HCV 
collaboration group 1994, our classification was 
carried-on. 
STATISTICAL ANALYSIS
Descriptive information is summarized as the total 
number of subject with and without history of 
blood transfusion along with number and 
percentage of subject with hepatitis C. for 
univariate analysis, the odds ratios (ORs) and 95% 
CIs were calculated from contingency tables. The 
OR represents the odds of HCV for subject with the 
risk factor (history of blood transfusion) relative to 
the odds of HCV for subject without risk factor. 
Multivariate analysis is summarized as an adjusted 
OR and 95% CI for dependent risk factor of blood 
transfusion identified by the multiple logistic 
regression models. All statistical tests were 
performed using p < 0.05. 
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RESULTS
A total of 387 units of whole blood were previously 
transfused to 151 mothers with a mean and range of
0.09 0.46, 1-8 units per woman. HCV antibody 
test (Anti-HCV) Lia Tek-III positivity was 
confirmed in 112 mother’s sera. Therefore the 
overall anti-HCV prevalence was 3.21%. History 
of previous blood transfusion, was accompanied, 
significantly, by higher prevalence of anti-HCV 
16.4% than their counter groups 2.5% (x2=95.96   
p=0.00001) (Table 1).
Table 1 Anti-HCV seropositivety (Lia-Tek III) and history of blood transfusion among 3491 
pregnant women in Iraq
History of Blood transifusion
Anti-HCV Status Present Absent Total
positive 28 (16.4) 84 (2.5) 112
Negative 143 3236 3379
Total 171 3320 3491
Interestingly, we found that with increased 
numbers of previous blood units transfused, was 
accompanied by significant increases of positive
anti-HCV sero-prevalence, in a range of (7.55-
58.33) (x2=255.11, p=0.00001) (Table 2). 
Moreover, significant direct positive correlation 
was detected between increased HCV sero-
prevalence and multiplicity of blood transfusion 
(r=0.74, p=0.046).
The association between potential risk 
factors of blood transfusion and HCV 
seropositivity was examined to develop a 
hypothesis on the modes of transmission of HCV. 
Our study revealed, that blood transfusion was 
strongly associated with HCV infection 
(OR=7.547, 95% C.I. 4.64-12.21). Calculating ORs 
separately for each unit of blood transfused verses 
non transfusion. The ORs showed steadily 
increasing values, with increasing amount of blood 
transfused. Therefore our study give evidence that 
strength of this association was significantly 
increases with increased amount of blood units 
transfused ranging OR=3.145-7.54 for 1-6 units 
of blood, with direct significant positive correlation 
r=0.98   p=0.0005.
Interestingly, using multivariate analysis, 
we found that blood transfusion was significantly 
acts as uncounfounding risk  factor acting 
independently  for acquisition of  HCV infection 
adjusted OR=1.938 95%C.1  1.646-2.281 (Table 3)
Table 2 The relation between anti-HCV seropositive rate and number of blood unit transfused 
Blood units Transfused
Anti  HCV 
serostatus
0 I II III IV V VI + Total
Positive 84(2.53) 8 (7.55) 3(10) 7(58.33) 3 (50) 4(44.44) 3(37.50) 112
Negative 3236 98 27 5 3 5 5 3379
Total 3320(95.1) 106(61.98) 30(17.5) 12(7.02) 6(3.5) 9(5.26) 8(4.67) 3491
x2=255.11, p=0.00001           r=0.74, S.E=16.68, p=0.046
Table 3 Crudr odds ratio (OR) of HCV infection correlated to number of blood unit transfused previously
Anti-HCV Positive OR 95% CI Significance
Transfusion Yes Vs No 7.543 4.640-12.21 S
Transfusion one unit Vs Nil 3.145 1.369-6.942 S
Transfusion two units Vs Nil 3.39 1.665-6.741 S
Transfusion three units Vs Nil 5.334 2.998-9.393 S
Transfusion four units Vs Nil 6.083 3.538-10.378 S
Transfusion  five units Vs Nil 6.970 4.204-11.524 S
Transfusion six + units Vs Nil 7.543 4.640-12.21 S
r=0.98      S.E= 0.4 p=0.0005.
Regarding RT-PCR and DEIA method, for 
the detection of HCV-RNA and its genotyping, and 
to investigate the association between potential risk 
of blood transfusion and presence of HCV-RNA. 
Our study detected significantly higher HCV-RNA 
prevalence (80%)  among 25 mothers with history 
of previous blood transfusion compared to (56.5%)  
those 69 with no such a history x2=4.04 p=0.04 
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with marginal significance of  OR =2.95 95% CI 
0.97-10.39  (Table 4)
Table 4 HCV-RNA prevalence among 94 pregnant women in relation to history of blood transfusion 
History of Blood transifusion
RT-PCR, HCV-RNA Present Absent Total
Positive 20   (80) 39   (56.5) 59
Negative 5 30 35
Total 25 69 94
OR =2.95   95% CI 0.97-10.39   x2=4.04 p=0.04 .
Genotyping of HCV
At least five HCV genotype/subtypes (1 1a 1b 
3a or 4) were circulating among Iraqi 
population. Either in a single (1 1a 1b or 4) or 
mixed (1+4, 1b+4; 3a+4) pattern of infection. 
The predominate HCV genotype among women 
with history of blood transfusion were HCV-4 
followed by HCV-1b. Interestingly, HCV-3a 
was absent in sera of women with history of 
blood transfusion. However, significant 
evidence of association between HCV 
genotypes and potential risk factors of previous 
blood transfusion was detected from our study. 
Table 5 HCV genotypic distribution according to history of blood transfusion
HCV Genotype &Subtypes
Blood tranfusion 1 1a 1b 4 1 & 4 1b & 4 3a & 4 Total
Present 3 3 4 5 1 4 - 20
Absent 2 10 6 8 2 6 3 37
Total 5 13 10 13 3 10 3 57
x2=2.32 , p=0.8  
DISCUSSION
Post transfusion hepatitis is a major public health 
problem world wide. HCV was characterized as 
parentally transmitted included blood and blood 
product15, 19, 20, 21, 22 and HCV was identified as a 
major cause of post transfusion hospital (PTH) 22, 
23. Therefore the parental spread of HCV, 
documented as unquestionable24. This issue was 
confirmed by our study  in which an evidence was 
presented that blood transfusion is a major and 
unconfounding risk factor for acquiring HCV 
infection among Iraqi pregnant women based on 
univariate, multivariate and logistic regression 
correlation (OR=1.936 95% C.I 1.64-2.28) adjusted 
OR= 7.54, 95% C.I.=4.6-12.7, r=0.98, p=0.00056  
respectively. PTHC virus antibody was found 
(16.37%) 6 times significantly greater than the 
counter group, and this values is less than (22%) 
that of French pregnant women25, but higher than 
(13%, 3.7%) of American and Italian women 
respectively26, 27. The most important finding of our 
investigation is the unconfounding risk factor of 
blood transfusion which was consistent with 
several studies among pregnant women in Mexico 
and Spain21,28 and population other than pregnant 
women24, 29, 30, 31 were OR, (95% C.I.) as 9.6 (4.4-
20.7), 3.2 (1.4-7.3), 2.4, 4.07 (2.9-5.6), 2.13 (1.32-
2.2) respectively. This variation may be due to the 
different assay system, HCV genotypes, stage of 
disease or strict screening strategy in blood donors 
selection as that in Swedish population (anti-
HCV0.026) 31. Although anti-HCV prevalence 
among Iraqi blood donors was about 0.5%32, 
unfortunately, blood screening for HCV was 
established since late 1995. This may partly explain 
the high prevalence of PTHC or it may be that 
blood units was collected during the window period 
of HCV seroconversion33. High parity34 and age of 
mother, however on the contrary, failed  to give 
any evidence for the significance of blood 
transfusion as a risk for transmission of HCV, 
neither by multivariate, nor by univariate35, 36, 37. 
Moreover our significant positive linear correlation 
between positive HCV and increased number of 
blood units transfused (r=0.7 P=0.046) was in 
contrast to other result38.
The astounding finding, that we confirmed 
the direct significant dose response correlation 
between number of blood unites transfused  and 
increased risk of exposure to HCV. Interestingly, it 
was started from the first blood unit transfused 
(OR=3.14 95% CI 1.3-6.94) onward disagreement 
to other31. To our knowledge this is the first attempt 
world wide to clarify without any doubt, the impact 
of number of blood units transfused on the 
acquisition of HCV among pregnant women. 
However, several authors reported such finding 
among population other than pregnant women30, 39, 
40. Moreover,  with history of blood transfusion our  
pregnant women showed significantly, higher rate 
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of HCV–RNA which was compatible with other 
finding22, 39, 41.This mean that such women were 
more likely to be viremic than their counter group. 
Regarding to genotypes and its relation to PTH, in 
consistent to study done42, we failed to detected 
such relation which was in contradict other studies, 
they found that the most predominant PTHC 
infection genotype was HCV-1b43,44,45,46. However 
we detected that genotype 4 or 1b (in a mixed or 
single pattern of infection) were the predominant 
circulating among PT HC women. A striking 
observation, we found that with increased number 
of blood units transfused ( >_   3) the possibility of 
HCV genotypes co-infection increases (data not 
shown). This confirmed other finding47, 48.
CONCLUSION
Post transfusion hepatitis is a major public health 
problem in Iraq is the blood transfusion acts as 
unconfounding risk factor for aquasition of HCV 
We gave evidence of direct significant dose 
response correlation between  number of blood 
unites transfused and increased risk of exposure to 
HCV.which was started from the first blood unit 
transfused onward . The predominant HCV 
genotype were HCV-4 and  1b ( in a mixed or 
single pattern of infection ) among PT HC in Iraq 
Therefore strict screening of blood donor for HCV-
Abs and / or RNA is highly recommend.
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